We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 25, 2021

Ponesimod vs Teriflunomide in Relapsing MS

JAMA Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Neurology
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial
JAMA Neurol 2021 May 01;78(5)558-567, L Kappos, RJ Fox, M Burcklen, MS Freedman, EK Havrdová, B Hennessy, R Hohlfeld, F Lublin, X Montalban, C Pozzilli, T Scherz, D D'Ambrosio, P Linscheid, A Vaclavkova, M Pirozek-Lawniczek, H Kracker, T Sprenger

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading